A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy

NCT07117175 | Not Yet Recruiting Early Phase 1

• 1 other identifier: SHSYXY-CAR-NK-CD7
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a single-arm, open-label, dose-escalation clinical trial to explore the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics of the drug; The efficacy of the study drug in subjects with relapsed/refractory CD7-positive hematological malignancies, and the expression of B cells, T cells, and NK cell subtypes in peripheral blood were preliminarily observed. At the same time, explporing the distribution of anti-human CD7 CAR-NK cells in tumor tissues after administration of anti-human CD7 CAR-NK cell injection, and evaluating the immunogenicity of anti-human CD7 CAR-NK cell injection . To evaluate the correlation between the proportion of CD7-positive tumor cells and the safety and efficacy of anti-human CD7 CAR-NK cell injection and the evaluation. To explore the pharmacokinetics (PK) and pharmacodynamics(PD) characteristics of bone marrow in Chinese medicine.

Conditions

Immunology; Hematologic Malignancies; CAR-NK

Outcome Measures

Primary Outcomes (2)

• Incidence of dose-limiting toxicity

  To evaluate the incidence of DLT in patients with relapsed or refractory CD7-Positive Hematological Malignancies treated with anti-human CD7 CAR-NK cell injection, DLT is defined as any of the following events related to the study drug (including definitely related, probably related, and possibly related) that occurs within 14-28 days after the first dose of the investigational human CD7 CAR-NK cell injection (with appropriately extended observation duration for responders in dose groups showing therapeutic responses to assess whether DLT events resolve within the specified time frame), despite therapeutic interventions.

  Up to day 28

• Incidence of adverse events

  The occurence of study related adverse effects defined by NCI CTCAE5.0

  through study completion, an average of 2 year

Secondary Outcomes (7)

• Evaluate the number of CAR-NK cells in subjects' peripheral blood

  Through study completion, an average of 2 year

• Analysis of the number changes of cytokine in peripheral blood.

  Through study completion, an average of 2 year

• Analysis of the number changes of lymphocyte subsets in peripheral blood.

  Through study completion, an average of 2 year

• Objective Response Rate (ORR)

  Through study completion, an average of 2 year

• Duration of response after administration (DOR)

  Through study completion, an average of 2 year

Study Arms (1)

Intravenous infusion of anti-human CD7 CAR-NK cell injection

EXPERIMENTAL

Infusion of anti-human CD7 CAR-NK cell injection at D0

Drug: Anti-human CD7 CAR-NK cell injection

Interventions

Anti-human CD7 CAR-NK cell injection DRUG

Administer anti-human CD7 CAR-NK cell injection on D0

Also known as: CD7 CAR-NK cell injection

Intravenous infusion of anti-human CD7 CAR-NK cell injection

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18-70 years old, gender is not limited;
• The expected survival time exceeds 12 weeks;
• ECOG score 0 to 2 points;
• Comply with the 2022 WHO standards for acute myeloid leukemia (AML), lymphoblastic lymphoma/leukemia (LBL/ALL), and after testing, CD7-positive flow cytometry leukemia cells expressed CD7 by ≥70%; or immunohistochemical leukemia cells expressed CD7 ≥50%. At the same time, it meets the following relapse-refractory standards:
• Recurrence criteria: ≥5% of the original cells appear in the bone marrow after hematologic remission (except for the hematopoietic recovery period after chemotherapy); or 2 peripheral blood samples at least one week intervals; or extramedullary lesions appear. Patients with early relapse (recuring within 12 months after the first remission) can be directly enrolled, while patients with advanced relapse (recuring after the first remission) need to rescue at least one course of chemotherapy through the original effective induction regimen and no remission is achieved; all relapse patients should include selectable targeted drugs for at least one course of treatment without remission. Allogeneic hematopoietic stem cells recur after transplantation, no other effective treatment options are available, and there is no active acute graft-versus-host disease (GVHD) above 2 degrees.
• Refractory criteria: Complete remission was not achieved at the end of induction therapy, and complete remission was not achieved after second-line rescue chemotherapy or the treatment regimen containing optional targeted drugs. Patients with tumor burden exceeding 5%, patients with persistent micro-residual lesions (MRD) positive, or patients with extramedullary lesions are also considered eligible.
• The intravenous pathway required for collection can be established, without contraindications for white blood cell collection;
• Liver and kidney function and cardiopulmonary function meet the following requirements:
• Creatinine clearance (calculated by Cockcroft Gault formula) ≥60 mL/min or creatinine ≤2.5×ULN;
• The cardiac ejaculation fraction is greater than 50%, and there is no clinically significant electrocardiogram change;
• Baseline blood oxygen saturation is greater than 92%;
• Total bilirubin ≤3×ULN; ALT and AST ≤3×ULN;
• Be able to understand this test and have signed an informed consent form.

You may not qualify if:

• Use of immunosuppressive drugs or steroids within two weeks prior to cell collection, or the need for steroid or immunosuppressive drug use for more than two years.
• History of malignancy other than hematologic neoplasms within five years before screening, except for adequately treated cervical carcinoma in situ, basal cell, or squamous cell skin cancer, localized prostate cancer after curative surgery, ductal carcinoma in situ after curative surgery, and thyroid cancer after curative surgery;
• Active bacterial, viral, or fungal infections requiring treatment and not controlled; positive HBsAg or HBcAb (if positive, peripheral HBV-DNA testing is required with HBV DNA \< detection limit to be eligible); positive HCV antibody with peripheral blood HCV RNA positivity; positive Treponema pallidum particle assay (TPPA); HIV antibody positivity;
• Inadequate function of major organs (cardiovascular system, lungs), active gastrointestinal bleeding within the past three months; uncontrolled hypertension or history of hypertensive crisis or hypertensive encephalopathy; significant cardiovascular risk history or evidence including any of the following: congestive heart failure, unstable angina pectoris, clinically significant arrhythmias (such as ventricular fibrillation, ventricular tachycardia); history of arterial thrombosis formation within the last three months (such as stroke, transient ischemic attack); symptomatic deep vein thrombosis or pulmonary embolism within six months prior to enrollment; previous coronary angioplasty procedure; cardioversion by electric shock; any clinically relevant complications that may pose a risk to the safety of the subject or interfere with study assessments, procedures, or completion;
• Any uncontrolled active disease that would preclude participation in the trial;
• Active and uncontrolled central nervous system involvement by disease process or a history thereof requiring treatment (e.g., epilepsy);
• Subjects receiving systemic corticosteroid therapy at screening who are expected to require long-term systemic corticosteroid therapy during the course of the study (inhaled and topical use excluded);
• Subjects who have used PD-1/PD-L1 monoclonal antibodies within three months prior to enrollment;
• Pregnant women and those lactating; subjects planning pregnancy within one year post-infusion or during/after treatment;
• Presence of uncontrollable active infection (simple urinary tract infection and upper respiratory tract infection excluded);
• Previous receipt of CAR-T/CAR-NK therapy or other genetically modified cellular therapies;
• Allogeneic transplant recipients without evident acute/chronic graft-versus-host disease and off immunosuppressive drugs for at least one month;
• Known allergy to any component of anti-human CD7 CAR-NK cell injection solution or chemotherapy regimen (cyclophosphamide and fludarabine);
• Any condition deemed by the investigator as likely to impair subject safety or interfere with study objectives; subjects considered unsuitable for this trial by investigators.
• Subjects unable to provide written informed consent due to illness affecting their ability to do so; unwillingness or inability to comply with study requirements.

Sponsors & Collaborators

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine: lead

Study Sites (1)

Shanghai General Hospital

Shanghai, Shanghai Municipality, 200080, China

Location

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Central Study Contacts

xianmin song, Doctor

CONTACT

18616705298; shongxm@139.com

jiahua niu, Master

CONTACT

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 4, 2025
• First Posted: August 12, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): December 15, 2027
• Study Completion (Estimated): January 30, 2028
• Last Updated: August 12, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)